Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial

Published on Aug 24, 2019in Inflammatory Bowel Diseases4.00
· DOI :10.1093/ibd/izz164
Freddy Caldera3
Estimated H-index: 3
(UW: University of Wisconsin-Madison),
Luke Hillman2
Estimated H-index: 2
(UW: University of Wisconsin-Madison)
+ 6 AuthorsMary S. Hayney20
Estimated H-index: 20
(UW: University of Wisconsin-Madison)
  • References (28)
  • Citations (0)
Published on Oct 12, 2018in Inflammatory Bowel Diseases4.00
Andrew Tinsley8
Estimated H-index: 8
(Penn State Milton S. Hershey Medical Center),
Seyedehsan Navabi2
Estimated H-index: 2
(Penn State Milton S. Hershey Medical Center)
+ 4 AuthorsKofi Clarke2
Estimated H-index: 2
(Penn State Milton S. Hershey Medical Center)
Published on May 17, 2018in Clinical Infectious Diseases9.05
Yoichiro Natori6
Estimated H-index: 6
(UHN: University Health Network),
Mika Shiotsuka1
Estimated H-index: 1
(UHN: University Health Network)
+ 9 AuthorsL.G. Singer40
Estimated H-index: 40
(UHN: University Health Network)
Published on Apr 23, 2018in Inflammatory Bowel Diseases4.00
Shimpei Shirai2
Estimated H-index: 2
(Saga University),
Megumi Hara24
Estimated H-index: 24
(Saga University)
+ 7 AuthorsRyuichi Iwakiri32
Estimated H-index: 32
(Saga University)
Published on Apr 1, 2018in The American Journal of Gastroenterology10.24
Gary R. Lichtenstein64
Estimated H-index: 64
(UPenn: University of Pennsylvania),
Edward Vincent Loftus81
Estimated H-index: 81
(Mayo Clinic)
+ 3 AuthorsBruce E. Sands68
Estimated H-index: 68
(ISMMS: Icahn School of Medicine at Mount Sinai)
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn's disease has evolved since th
Published on May 1, 2017in Gut17.94
Jean-Frederic Colombel126
Estimated H-index: 126
(ISMMS: Icahn School of Medicine at Mount Sinai),
Bruce E. Sands68
Estimated H-index: 68
(ISMMS: Icahn School of Medicine at Mount Sinai)
+ 11 AuthorsI. Fox13
Estimated H-index: 13
(Takeda Pharmaceutical Company)
Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-y...
Published on Feb 1, 2017in The American Journal of Gastroenterology10.24
Francis A. Farraye49
Estimated H-index: 49
Gil Y. Melmed31
Estimated H-index: 31
+ 1 AuthorsSunanda V. Kane46
Estimated H-index: 46
Recent data suggest that inflammatory bowel disease (IBD) patients do not receive preventive services at the same rate as general medical patients. Patients with IBD often consider their gastroenterologist to be the primary provider of care. To improve the care delivered to IBD patients, health main
Published on Sep 27, 2016in Oncotarget
Raj K. Kurupati10
Estimated H-index: 10
Andrew V. Kossenkov29
Estimated H-index: 29
+ 8 AuthorsLouise C. Showe43
Estimated H-index: 43
// Raj Kurupati 1,* , Andrew Kossenkov 1,* , Larissa Haut 1 , Senthil Kannan 1,2 , Zhiquan Xiang 1 , Yan Li 1 , Susan Doyle 3 , Qin Liu 1 , Kenneth Schmader 3 , Louise Showe 1 and Hildegund Ertl 1 1 The Wistar Institute, Philadelphia, PA, USA 2 Biomedical Graduate Group, University of Pennsylvania, Philadelphia, PA, USA 3 Development and Division of Geriatrics, GRECC, Durham VA Medical Center and Center for the Study of Aging and Human, Department of Medicine, Duke University Medical Center, Dur...
Published on Aug 7, 2015in Morbidity and Mortality Weekly Report14.87
Lisa A. Grohskopf22
Estimated H-index: 22
(CDC: Centers for Disease Control and Prevention),
Leslie Z. Sokolow11
Estimated H-index: 11
(CDC: Centers for Disease Control and Prevention)
+ 3 AuthorsRuth A. Karron48
Estimated H-index: 48
(Johns Hopkins University)
This report updates the 2014 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines. Updated information for the 2015-16 season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) information on influenza vaccine products expected to be available for the 2015-16 season; 3) an updated algorithm for determining the appropriate number of doses for children aged 6 months through 8 years; and 4) recommendations...
Published on Apr 1, 2016in The American Journal of Gastroenterology10.24
Wichmann A1
Estimated H-index: 1
Krugliak Cleveland N1
Estimated H-index: 1
David T. Rubin48
Estimated H-index: 48
Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab
Published on Mar 1, 2016in Inflammatory Bowel Diseases4.00
Jennifer deBruyn13
Estimated H-index: 13
(Alberta Children's Hospital),
Kevin Fonseca24
Estimated H-index: 24
+ 6 AuthorsIwona Wrobel13
Estimated H-index: 13
(Alberta Children's Hospital)
Abstract In patients with inflammatory bowel disease (IBD) on infliximab, data are limited on immune response to influenza vaccine and the impact of vaccine timing. The study aims were to evaluate immune responses to the influenza vaccine in IBD patients on infliximab and the impact of vaccine timing on immune responses. In this randomized study, 137 subjects with IBD on maintenance infliximab therapy were allocated to receive the 2012/2013 inactivated influenza vaccine at the time of infliximab...
Cited By0